Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 8/20 | 0.43 |
| ▸ | FDPS | P14324 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578667 | 0.98 | LPAR1 (0.52) | LPAR1LPAR3CES2FAAHFDPS | |
| SCHEMBL27324891 | 0.98 | LPAR1 (0.52) | LPAR1LPAR3CES2FAAHFDPS | |
| SCHEMBL20654833 | 0.98 | LPAR1 (0.52) | LPAR1LPAR3CES2FAAHFDPS | |
| SCHEMBL1031370 | 0.81 | — | — | |
| SCHEMBL8182272 | 0.78 | CES2 (0.42) | LPAR1LPAR3CES2FAAHFDPS | |
| SCHEMBL3759471 | 0.75 | CES2 (0.39) | LPAR1LPAR3CES2FAAHCES1 | |
| SCHEMBL3896366 | 0.74 | TSHR (0.42) | FAAHFDPSGGPS1 | |
| SCHEMBL24113952 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL19837802 | 0.73 | TSHR (0.42) | LPAR1LPAR3CES2FAAHCES1 | |
| SCHEMBL20654770 | 0.73 | CYP4F2 (0.34) | LPAR1LPAR3MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925945-A1 | METHOD FOR PRODUCING FLUORINATED COMPOUND | Daikin Industries, Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC. | 2018-12-13 | — | — | US | disclosed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | LPAR1 3432/4885LPAR3 2828/4885CES2 3515/4885 |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | LPAR1 3432/4885LPAR3 2828/4885CES2 3515/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | LPAR1 3259/4885LPAR3 2546/4885CES2 3435/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | LPAR1 3460/4885LPAR3 2870/4885CES2 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.